Targeting endothelial MYC using nanoparticles bearing siRNA or miRNA is an efficient strategy for tumor anti-angiogenic therapy to enhance the efficacy of chemo- and immune checkpoint inhibitor-based immuno-therapies. This evidence concerns the gene MYC and neoplasm.